Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).

Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia’s role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.